BIODELIVERY SCIENCES INTL (BDSI) Stock Price, Forecast & Analysis
USA - NASDAQ:BDSI - Common Stock
BDSI Key Statistics, Chart & Performance
The current stock price of BDSI is 5.59 null. In the past month the price increased by 0.72%. In the past year, price increased by 53.15%.
BDSI Latest News, Press Relases and Analysis
BDSI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.7 | 992.71B | ||
| JNJ | JOHNSON & JOHNSON | 19.46 | 486.52B | ||
| MRK | MERCK & CO. INC. | 10.95 | 240.94B | ||
| PFE | PFIZER INC | 7.9 | 143.73B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.08 | 94.51B | ||
| ZTS | ZOETIS INC | 18.44 | 51.83B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.44 | 22.62B | ||
| VTRS | VIATRIS INC | 4.51 | 12.25B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.35 | 10.66B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.13 | 7.89B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.40B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.24B |
Related stock screener links
About BDSI
Company Profile
BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. The company is headquartered in Raleigh, North Carolina and currently employs 200 full-time employees. The company went IPO on 2002-06-25. The firm focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The firm's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.
Company Info
BIODELIVERY SCIENCES INTL
4131 Parklake Ave Ste 225
Raleigh NORTH CAROLINA 27612 US
CEO: Jeffrey Bailey
Employees: 200
Phone: 19195829050.0
BIODELIVERY SCIENCES INTL / BDSI FAQ
What does BIODELIVERY SCIENCES INTL do?
BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. The company is headquartered in Raleigh, North Carolina and currently employs 200 full-time employees. The company went IPO on 2002-06-25. The firm focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The firm's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.
What is the stock price of BIODELIVERY SCIENCES INTL today?
The current stock price of BDSI is 5.59 null. The price decreased by -0.09% in the last trading session.
Does BDSI stock pay dividends?
BDSI does not pay a dividend.
How is the ChartMill rating for BIODELIVERY SCIENCES INTL?
BDSI has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
On which exchange is BDSI stock listed?
BDSI stock is listed on the Nasdaq exchange.
What is the analyst forecast for BDSI stock?
13 analysts have analysed BDSI and the average price target is 5.48 null. This implies a price decrease of -1.88% is expected in the next year compared to the current price of 5.59.
What is BIODELIVERY SCIENCES INTL worth?
BIODELIVERY SCIENCES INTL (BDSI) has a market capitalization of 552.29M null. This makes BDSI a Small Cap stock.
BDSI Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to BDSI. When comparing the yearly performance of all stocks, BDSI is one of the better performing stocks in the market, outperforming 97.69% of all stocks.
BDSI Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to BDSI. While BDSI belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
BDSI Financial Highlights
Over the last trailing twelve months BDSI reported a non-GAAP Earnings per Share(EPS) of 0.83. The EPS increased by 232% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 50.91% | ||
| ROA | 26.14% | ||
| ROE | 45.18% | ||
| Debt/Equity | 0.29 |
BDSI Forecast & Estimates
13 analysts have analysed BDSI and the average price target is 5.48 null. This implies a price decrease of -1.88% is expected in the next year compared to the current price of 5.59.
For the next year, analysts expect an EPS growth of -57.48% and a revenue growth 22.27% for BDSI